The big news in David Systrom’s “Neurovascular Dysregulation Underlies Exercise Intolerance in ME/CFS” talk at the CDC yesterday was that the $8 million mitochondrial drug trial had, unfortunately, failed. The ME/CFS Mitochondrial Drug Trial Fails...
This University of Colorado/ National Jewish Health Center study, “Signatures of Mitochondrial Dysfunction and Impaired Fatty Acid Metabolism in Plasma of Patients with Post-Acute Sequelae of COVID-19 (PASC)”, follows on the heels of another study...
The 4th in a series of blogs on the 2022 IACFS/ME International Conference finds two new metabolomic studies that highlighted three problems that have cropped up recently in other studies: fatty acid metabolism, cell membrane damage, and energy production. The first...
Step by step Lipkin’s metabolomic study produces a coherent picture of mitochondrial dysfunction The really neat thing about Ian Lipkin’s latest work on ME/CFS is how well all the results fit together. Health Rising reported on the preprint of this...
Ron Davis gets a win but will he ever be given the chance to bring his core disrupting technologies to ME/CFS? An ME/CFS Moment: something unexpected happens that indicates the tide is rising for the ME/CFS field. This could include something like a big grant...
An $8 million clinical trial of a mitochondrial enhancer, no less, in ME/CFS? I thought I was hearing things but it was so, and, in the end, it even makes sense given how rapidly some parts of this field are moving forward. But first, a little backstory. A...
